News

BluSky raises $140K for ALS research at Miller Lab in St. Louis

Continuing its annual support, BluSky Restoration Contractors has raised $140,000 to advance research at the Miller Laboratory at Washington University School of Medicine in St. Louis, Missouri, for new and better amyotrophic lateral sclerosis (ALS) treatments. The funds were raised through the sixth annual Rakers Classic…

New EAP will make CNM-Au8 available outside of trials

The National Institutes of Health (NIH) has awarded about $45.1 million toward an expanded access program (EAP) of CNM-Au8, an oral therapy candidate for amyotrophic lateral sclerosis (ALS). The EAP, commonly referred to as compassionate use, will make CNM-Au8 available to U.S. patients who aren’t eligible for clinical…

Interferon-gamma therapy may help delay familial ALS: Cell study

People with amyotrophic lateral sclerosis (ALS) due to mutations in the FUS gene may benefit from interferon-gamma treatment to delay disease onset and/or progression, an early preclinical study suggests. Researchers found that an immune signaling protein called interferon (INF)-gamma protected patient-derived motor neurons from oxidative stress. INF-gamma also restored…

NIH grant will help launch the ALL ALS research consortium

The Barrow Neurological Institute has received $16.7 million from the National Institutes of Health (NIH) to help coordinate a nationwide repository of clinical data of people with amyotrophic lateral sclerosis (ALS). The Access for All in ALS (ALL ALS) Consortium will serve as a repository of biological samples and clinical…

PrimeC boosts survival of motor neurons derived from ALS patients

PrimeC, NeuroSense Therapeutics‘ investigational, fixed-dose combination therapy for amyotrophic lateral sclerosis (ALS), significantly boosted the survival of patient-derived motor neurons to levels similar to healthy controls in a lab study. The independent study was led by Justin Ichida, PhD, a professor of stem cell biology and regenerative…

Cytokinetics calls for proposals for 6th Communications Grant Program

Cytokinetics is calling for proposals from patient advocacy organizations focused on amyotrophic lateral sclerosis (ALS) and cardiovascular conditions for its 6th annual Communications Grant Program. The 2024 program will award five grants totaling $20,000 each to groups serving the ALS, heart failure, and hypertrophic cardiomyopathy communities. These…